Latest news with #InnovativeMedicine
Yahoo
17-07-2025
- Business
- Yahoo
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Highlights: Strong Sales Growth Amid Challenges
Worldwide Sales: $23.7 billion, a 4.6% increase. Innovative Medicine Sales: $15.2 billion, a 3.8% increase. MedTech Sales: $8.5 billion, a 6.1% increase. Net Earnings: $5.5 billion. Diluted Earnings Per Share (EPS): $2.29, up from $1.93 a year ago. Adjusted Net Earnings: $6.7 billion. Adjusted Diluted EPS: $2.77, a 1.8% decrease from the previous year. Operational Sales Growth: 4.6% overall, 3.8% in Innovative Medicine, 6.1% in MedTech. Oncology Sales Growth: 22.3% operational growth. Cardiovascular Sales Growth: Over 22% operational growth. Free Cash Flow: Exceeded $6 billion in the first half of 2025. Cash and Marketable Securities: $19 billion. Debt: $51 billion, resulting in a net debt position of $32 billion. Effective Tax Rate: 14.7% for the quarter. Full-Year Sales Guidance Increase: Raised by $2 billion. Full-Year EPS Guidance Increase: Raised by $0.25 to a range of $10.80 to $10.90. Warning! GuruFocus has detected 8 Warning Signs with CGEAF. Release Date: July 16, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Johnson & Johnson (NYSE:JNJ) reported a strong operational sales growth of 4.6% across its business in the second quarter of 2025. The company achieved over $15 billion in quarterly sales for the first time in its Innovative Medicine segment, despite the loss of exclusivity for STELARA. MedTech division delivered 6.1% operational sales growth, with significant momentum in cardiovascular surgery. Johnson & Johnson (NYSE:JNJ) raised its full-year sales guidance by $2 billion and EPS guidance by $0.25. The company is making significant progress in oncology, with a 22.3% operational sales growth and a bold vision to become the number one oncology company by 2030. Negative Points The loss of exclusivity for STELARA posed a significant headwind, impacting sales by approximately 710 basis points. Adjusted net earnings for the quarter decreased by 2.1% compared to the second quarter of 2024. The orthopedics business declined by 1.6%, driven by competitive pressures and transformation programs. MedTech margin declined from 25.7% to 22.2% due to macroeconomic factors and cost of products sold. Interest income and expense shifted to a net expense of $48 million from $125 million of income in the second quarter of 2024, primarily due to lower interest rates and higher debt from acquisitions. Q & A Highlights Q: J&J reported strong top-line growth despite the STELARA loss of exclusivity. What are the main drivers of this growth, and how do the Innovative Medicine and MedTech segments contribute? A: Joseph Wolk, CFO, highlighted that both segments contributed significantly to the strong performance. Jennifer Taubert, EVP of Innovative Medicine, noted that the business achieved its first $15 billion quarter, with 13 brands growing double digits. Tim Schmid, EVP of MedTech, mentioned cardiovascular growth of 22% and strong performance in vision and surgery as key contributors. Q: Can you elaborate on the oncology target of $50 billion by the end of the decade? What are the key growth areas? A: Jennifer Taubert, EVP of Innovative Medicine, expressed confidence in the $50 billion target, citing strong growth in multiple myeloma with DARZALEX and CARVYKTI, and the potential of TAR-200 in bladder cancer. John Reed, EVP of R&D, added that the oncology pipeline has strong momentum, with promising developments in colorectal and head and neck cancers. Q: The guidance implies an acceleration in top-line growth in the second half of the year. Can you comment on the potential for growth in 2026 and beyond? A: Joseph Wolk, CFO, indicated that 2026 is expected to see better growth than 2025, driven by new product introductions and in-line brands receiving new indications. He also mentioned that margin improvement will be assessed as the year progresses. Q: How is J&J preparing for the potential impact of pharma tariffs, and what is the flexibility of your manufacturing supply chain in the US? A: Joaquin Duato, CEO, stated that J&J is committed to manufacturing in the US and has a plan to invest $55 billion over the next four years to ensure that all medicines consumed in the US are manufactured domestically. Q: Can you provide an update on the OTTAVA Robotic Surgical System and the electrophysiology (EP) strategy? A: Tim Schmid, EVP of MedTech, confirmed that OTTAVA is on track with its milestones, with a de novo submission expected in the first quarter of next year. He also highlighted the strong performance in EP, driven by the adoption of VARIPULSE and the strategic differentiation of the Cardio systems. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Wire
16-07-2025
- Business
- Business Wire
Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. 'Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating across both MedTech and Innovative Medicine,' said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. 'Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways.' Overall financial results 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine 6 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 7 Second-quarter YTD 2025 is estimated as of July 16, 2025 Note: values may have been rounded Expand Regional sales results 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Expand Segment sales results 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Expand Second-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 3.8%*, with net acquisitions and divestitures positively impacting growth by 1.4%. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (1,170) basis points impact from STELARA in Immunology, and an approximate (130) basis points impact from COVID-19 in Infectious Diseases. MedTech MedTech worldwide operational sales grew 6.1%*, with net acquisitions and divestitures positively impacting growth by 2.0%. Growth was primarily driven by electrophysiology products and Abiomed in Cardiovascular, as well as wound closure products in General Surgery. Full-year 2025 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: July 2025 = $1.13 and April 2025 = $1.10 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Note: percentages may have been rounded Expand Other modeling considerations will be provided on the webcast Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company's website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at Non-GAAP financial measures: * 'Operational sales growth' excluding the impact of translational currency, 'adjusted operational sales growth' excluding the net impact of acquisitions and divestitures and translational currency, as well as 'adjusted net earnings', 'adjusted diluted earnings per share' and 'adjusted operational diluted earnings per share' excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to investors concerning forward-looking statements: This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) SECOND QUARTER Sales to customers by geographic area U.S. $ 13,544 12,569 7.8 % 7.8 - $ 25,849 24,189 6.9 % 6.9 - Europe 5,387 5,214 3.3 (1.9 ) 5.2 10,497 10,377 1.1 0.2 0.9 Western Hemisphere excluding U.S. 1,206 1,212 (0.5 ) 6.2 (6.7 ) 2,373 2,406 (1.3 ) 7.7 (9.0 ) Asia-Pacific, Africa 3,606 3,452 4.4 2.4 2.0 6,917 6,858 0.9 0.9 0.0 International 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7 ) Worldwide $ 23,743 22,447 5.8 % 4.6 1.2 $ 45,636 43,830 4.1 % 4.4 (0.3 ) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Expand Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) SIX MONTHS 2025 2024 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 45,636 100.0 $ 43,830 100.0 4.1 Cost of products sold 14,985 32.8 13,380 30.5 12.0 Gross Profit 30,651 67.2 30,450 69.5 0.7 Selling, marketing and administrative expenses 11,001 24.1 10,938 25.0 0.6 Research and development expense 6,741 14.8 6,982 16.0 (3.5 ) In-process research and development impairments - - 194 0.4 Interest (income) expense, net (80 ) (0.2 ) (334 ) (0.8 ) Other (income) expense, net (7,214 ) (15.8 ) 3,057 7.0 Restructuring 81 0.2 151 0.3 Earnings before provision for taxes on income 20,122 44.1 9,462 21.6 112.7 Provision for taxes on income 3,586 7.9 1,521 3.5 135.8 Net earnings $ 16,536 36.2 $ 7,941 18.1 108.2 Net earnings per share (Diluted) $ 6.82 $ 3.27 108.6 Average shares outstanding (Diluted) 2,423.3 2,428.5 Effective tax rate 17.8 % 16.1 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income $ 16,199 35.5 $ 16,281 37.1 (0.5 ) Net earnings $ 13,405 29.4 $ 13,420 30.6 (0.1 ) Net earnings per share (Diluted) $ 5.53 $ 5.53 0.0 Effective tax rate 17.2 % 17.6 % (1) See Reconciliation of Non-GAAP Financial Measures. Expand Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Second Quarter Six Months Ended (Dollars in Millions Except Per Share Data) 2025 2024 2025 2024 Net Earnings, after tax- as reported $5,537 $4,686 $16,536 $7,941 Pre-tax Adjustments Litigation related 57 352 (6,909) 3,078 Intangible Asset Amortization expense 1,267 1,106 2,387 2,184 COVID-19 Vaccine related costs - 64 - 73 Restructuring related 1 79 (11) 134 160 Medical Device Regulation - 68 - 119 Acquisition, integration and divestiture related 246 452 378 600 (Gains)/losses on securities 21 431 60 411 IPR&D impairments - 194 - 194 Other 27 - 27 - Tax Adjustments Tax impact on special item adjustments 2 (321) (437) 994 (1,293) Tax legislation and other tax related (214) (65) (202) (47) Adjusted Net Earnings , after tax $6,699 $6,840 $13,405 $13,420 Average shares outstanding (Diluted) 2,419.1 2,422.0 2,423.3 2,428.5 Adjusted net earnings per share (Diluted) $2.77 $2.82 $5.53 $5.53 Operational adjusted net earnings per share (Diluted) $2.71 $5.52 Notes: 1 In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring income of $63 million in the fiscal second quarter of 2024 ($81 million expense Q2 2024 YTD) included asset divestments and the termination of partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) and $52 million in the fiscal second quarter of 2024 ($79 million Q2 2024 YTD) includes costs related to market and product exits. In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $29 million were recorded in the fiscal second quarter of 2025. 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Expand REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) % Change % Change ONCOLOGY US $ 3,385 2,636 28.4 % 28.4 % - $ 6,398 5,019 27.5 % 27.5 % - Intl 2,928 2,455 19.3 % 15.7 % 3.6 % 5,592 4,885 14.5 % 15.1 % -0.6 % WW 6,312 5,090 24.0 % 22.3 % 1.7 % 11,990 9,904 21.1 % 21.3 % -0.2 % CARVYKTI US 358 167 * * - 676 307 * * - Intl 81 20 * * * 132 36 * * * WW 439 186 * * * 808 343 * * * DARZALEX US 2,017 1,641 23.0 % 23.0 % - 3,846 3,105 23.9 % 23.9 % - Intl 1,521 1,237 23.0 % 19.6 % 3.4 % 2,930 2,465 18.9 % 19.7 % -0.8 % WW 3,539 2,878 23.0 % 21.5 % 1.5 % 6,776 5,570 21.7 % 22.0 % -0.3 % ERLEADA US 378 318 18.6 % 18.6 % - 670 603 11.0 % 11.0 % - Intl 530 418 27.0 % 22.8 % 4.2 % 1,009 822 22.9 % 23.0 % -0.1 % WW 908 736 23.4 % 21.0 % 2.4 % 1,679 1,425 17.8 % 17.9 % -0.1 % IMBRUVICA US 239 246 -2.7 % -2.7 % - 474 511 -7.3 % -7.3 % - Intl 496 525 -5.4 % -8.4 % 3.0 % 970 1,043 -6.9 % -6.3 % -0.6 % WW 735 770 -4.5 % -6.6 % 2.1 % 1,444 1,554 -7.0 % -6.6 % -0.4 % RYBREVANT / LAZCLUZE (3) US 139 52 * * - 252 88 * * - Intl 41 17 * * * 69 28 * * * WW 179 69 * * * 320 116 * * * TALVEY US 82 59 38.0 % 38.0 % - 150 109 36.7 % 36.7 % - Intl 24 9 * * * 42 17 * * * WW 106 69 55.0 % 54.3 % 0.7 % 192 127 52.0 % 52.4 % -0.4 % TECVAYLI US 114 104 8.2 % 8.2 % - 219 205 6.6 % 6.6 % - Intl 52 30 74.8 % 72.0 % 2.8 % 98 63 56.0 % 58.4 % -2.4 % WW 166 135 23.1 % 22.4 % 0.7 % 317 268 18.2 % 18.7 % -0.5 % ZYTIGA / abiraterone acetate US 6 11 -38.9 % -38.9 % - 13 20 -31.9 % -31.9 % - Intl 139 154 -9.8 % -13.3 % 3.5 % 257 326 -21.1 % -21.3 % 0.2 % WW 145 165 -11.6 % -14.9 % 3.3 % 270 346 -21.7 % -21.9 % 0.2 % OTHER ONCOLOGY US 50 37 36.9 % 36.9 % - 97 70 39.8 % 39.8 % - Intl 42 45 -8.7 % -12.3 % 3.6 % 84 86 -2.5 % -1.8 % -0.7 % WW 93 83 11.7 % 9.7 % 2.0 % 182 156 16.4 % 16.8 % -0.4 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change IMMUNOLOGY US $ 2,505 2,978 -15.9 % -15.9 % - $ 4,701 5,431 -13.4 % -13.4 % - Intl 1,489 1,744 -14.6 % -16.2 % 1.6 % 2,999 3,538 -15.2 % -13.8 % -1.4 % WW 3,993 4,722 -15.4 % -16.0 % 0.6 % 7,700 8,969 -14.1 % -13.6 % -0.5 % REMICADE US 283 231 22.5 % 22.5 % - 597 497 20.1 % 20.1 % - US Exports (4) 34 35 -2.6 % -2.6 % - 44 62 -28.7 % -28.7 % - Intl 138 127 8.6 % 8.8 % -0.2 % 281 268 4.8 % 7.7 % -2.9 % WW 455 393 15.9 % 15.9 % 0.0 % 922 827 11.5 % 12.4 % -0.9 % SIMPONI / SIMPONI ARIA US 305 267 14.0 % 14.0 % - 597 521 14.4 % 14.4 % - Intl 387 270 43.1 % 40.8 % 2.3 % 753 569 32.2 % 35.0 % -2.8 % WW 690 537 28.6 % 27.5 % 1.1 % 1,349 1,091 23.7 % 25.1 % -1.4 % STELARA US 1,078 1,855 -41.9 % -41.9 % - 2,059 3,251 -36.7 % -36.7 % - Intl 575 1,030 -44.2 % -45.6 % 1.4 % 1,219 2,085 -41.5 % -40.6 % -0.9 % WW 1,653 2,885 -42.7 % -43.2 % 0.5 % 3,278 5,336 -38.6 % -38.2 % -0.4 % TREMFYA US 796 589 35.2 % 35.2 % - 1,395 1,098 27.1 % 27.1 % - Intl 391 317 23.2 % 20.5 % 2.7 % 747 616 21.2 % 22.4 % -1.2 % WW 1,186 906 31.0 % 30.1 % 0.9 % 2,142 1,714 25.0 % 25.4 % -0.4 % OTHER IMMUNOLOGY US 8 2 * * - 9 2 * * - Intl 0 0 - - - 0 0 - - - WW 8 2 * * - 9 2 * * - NEUROSCIENCE US 1,377 1,102 24.9 % 24.9 % - 2,345 2,156 8.7 % 8.7 % - Intl 674 679 -0.8 % -2.6 % 1.8 % 1,353 1,428 -5.2 % -4.1 % -1.1 % WW 2,051 1,782 15.1 % 14.4 % 0.7 % 3,698 3,585 3.2 % 3.6 % -0.4 % CAPLYTA (5) US 211 - * * - 211 - * * - Intl - - - - - - - - - - WW 211 - * * - 211 - * * - CONCERTA / Methylphenidate US 24 34 -27.7 % -27.7 % - 62 75 -16.6 % -16.6 % - Intl 139 129 7.5 % 7.0 % 0.5 % 249 265 -6.0 % -4.4 % -1.6 % WW 164 163 0.2 % -0.2 % 0.4 % 312 340 -8.3 % -7.1 % -1.2 % INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 732 784 -6.7 % -6.7 % - 1,357 1,549 -12.4 % -12.4 % - Intl 260 269 -3.5 % -5.1 % 1.6 % 537 561 -4.2 % -3.1 % -1.1 % WW 992 1,054 -5.9 % -6.3 % 0.4 % 1,895 2,110 -10.2 % -9.9 % -0.3 % SPRAVATO US 366 226 61.1 % 61.1 % - 642 417 53.7 % 53.7 % - Intl 50 44 12.8 % 11.0 % 1.8 % 93 78 18.1 % 20.1 % -2.0 % WW 414 271 53.3 % 53.0 % 0.3 % 734 496 48.1 % 48.4 % -0.3 % OTHER NEUROSCIENCE US 45 57 -23.5 % -23.5 % - 73 115 -37.0 % -37.0 % - Intl 226 237 -4.7 % -7.6 % 2.9 % 474 524 -9.5 % -8.8 % -0.7 % WW 270 294 -8.4 % -10.7 % 2.3 % 547 639 -14.4 % -13.9 % -0.5 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change PULMONARY HYPERTENSION US $ 799 743 7.6 % 7.6 % - $ 1,543 1,509 2.3 % 2.3 % - Intl 314 296 5.8 % 2.8 % 3.0 % 595 579 2.6 % 3.0 % -0.4 % WW 1,113 1,039 7.1 % 6.2 % 0.9 % 2,138 2,088 2.4 % 2.5 % -0.1 % OPSUMIT / OPSYNVI US 403 376 6.9 % 6.9 % - 766 732 4.6 % 4.6 % - Intl 180 171 5.4 % 2.1 % 3.3 % 339 340 -0.3 % -0.2 % -0.1 % WW 582 548 6.4 % 5.4 % 1.0 % 1,104 1,072 3.0 % 3.1 % -0.1 % UPTRAVI US 382 349 9.4 % 9.4 % - 747 741 0.8 % 0.8 % - Intl 94 76 22.4 % 19.8 % 2.6 % 180 152 17.9 % 18.7 % -0.8 % WW 476 426 11.7 % 11.3 % 0.4 % 927 894 3.7 % 3.8 % -0.1 % OTHER PULMONARY HYPERTENSION US 16 17 -12.4 % -12.4 % - 31 35 -12.6 % -12.6 % - Intl 40 49 -18.5 % -21.3 % 2.8 % 77 88 -12.4 % -12.1 % -0.3 % WW 55 67 -16.9 % -19.0 % 2.1 % 107 123 -12.5 % -12.3 % -0.2 % INFECTIOUS DISEASES US 320 334 -4.3 % -4.3 % - 635 658 -3.6 % -3.6 % - Intl 484 631 -23.4 % -26.8 % 3.4 % 971 1,128 -13.9 % -14.1 % 0.2 % WW 803 965 -16.8 % -19.0 % 2.2 % 1,605 1,786 -10.1 % -10.2 % 0.1 % EDURANT / rilpivirine US 6 8 -25.4 % -25.4 % - 14 16 -13.6 % -13.6 % - Intl 354 288 23.0 % 16.7 % 6.3 % 704 603 16.7 % 15.6 % 1.1 % WW 360 297 21.6 % 15.5 % 6.1 % 718 620 15.9 % 14.9 % 1.0 % PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 312 321 -3.0 % -3.0 % - 617 635 -2.9 % -2.9 % - Intl 85 117 -27.0 % -29.4 % 2.4 % 183 221 -17.2 % -15.8 % -1.4 % WW 396 438 -9.4 % -10.0 % 0.6 % 799 856 -6.6 % -6.3 % -0.3 % OTHER INFECTIOUS DISEASES US 2 5 -51.8 % -51.8 % - 4 7 -37.4 % -37.4 % - Intl 45 227 -80.5 % -80.6 % 0.1 % 84 304 -72.5 % -72.1 % -0.4 % WW 47 233 -79.8 % -79.9 % 0.1 % 88 311 -71.7 % -71.3 % -0.4 % CARDIOVASCULAR / METABOLISM / OTHER US 776 717 8.2 % 8.2 % - 1,631 1,348 21.0 % 21.0 % - Intl 154 176 -12.3 % -13.2 % 0.9 % 312 373 -16.2 % -14.3 % -1.9 % WW 930 892 4.2 % 4.0 % 0.2 % 1,943 1,721 12.9 % 13.3 % -0.4 % XARELTO US 621 587 5.6 % 5.6 % - 1,311 1,105 18.6 % 18.6 % - Intl - - - - - - - - - - WW 621 587 5.6 % 5.6 % - 1,311 1,105 18.6 % 18.6 % - OTHER US 155 129 20.0 % 20.0 % - 320 243 31.6 % 31.6 % - Intl 154 176 -12.3 % -13.2 % 0.9 % 312 373 -16.2 % -14.3 % -1.9 % WW 309 305 1.4 % 0.9 % 0.5 % 632 616 2.7 % 3.9 % -1.2 % TOTAL INNOVATIVE MEDICINE US 9,161 8,510 7.6 % 7.6 % - 17,253 16,122 7.0 % 7.0 % - Intl 6,041 5,980 1.0 % -1.6 % 2.6 % 11,822 11,930 -0.9 % -0.1 % -0.8 % WW $ 15,202 14,490 4.9 % 3.8 % 1.1 % $ 29,075 28,052 3.6 % 4.0 % -0.4 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change CARDIOVASCULAR US $ 1,364 1,119 21.9 % 21.9 % - $ 2,625 2,144 22.4 % 22.4 % - Intl 948 753 25.9 % 22.9 % 3.0 % 1,790 1,534 16.7 % 16.7 % 0.0 % WW 2,313 1,873 23.5 % 22.3 % 1.2 % 4,416 3,679 20.0 % 20.0 % 0.0 % ELECTROPHYSIOLOGY US 741 705 5.1 % 5.1 % - 1,425 1,397 2.0 % 2.0 % - Intl 728 618 17.8 % 15.2 % 2.6 % 1,366 1,270 7.6 % 7.8 % -0.2 % WW 1,468 1,323 11.0 % 9.8 % 1.2 % 2,791 2,667 4.7 % 4.7 % 0.0 % ABIOMED US 360 309 16.6 % 16.6 % - 699 612 14.2 % 14.2 % - Intl 89 72 25.0 % 18.4 % 6.6 % 170 139 22.4 % 20.9 % 1.5 % WW 448 379 18.2 % 16.9 % 1.3 % 868 750 15.7 % 15.5 % 0.2 % SHOCKWAVE (6) US 233 77 * * - 439 77 * * - Intl 58 0 * * * 110 0 * * * WW 292 77 * * * 550 77 * * - OTHER CARDIOVASCULAR US 31 29 5.4 % 5.4 % - 63 59 6.3 % 6.3 % - Intl 72 64 13.4 % 11.6 % 1.8 % 144 126 14.2 % 14.5 % -0.3 % WW 104 93 10.8 % 9.7 % 1.1 % 207 185 11.7 % 11.8 % -0.1 % ORTHOPAEDICS US 1,420 1,422 -0.2 % -0.2 % - 2,804 2,870 -2.3 % -2.3 % - Intl 885 890 -0.5 % -4.0 % 3.5 % 1,742 1,782 -2.2 % -2.4 % 0.2 % WW 2,305 2,312 -0.3 % -1.6 % 1.3 % 4,546 4,652 -2.3 % -2.3 % 0.0 % HIPS US 271 265 2.1 % 2.1 % - 534 535 -0.2 % -0.2 % - Intl 150 152 -1.0 % -4.3 % 3.3 % 296 304 -2.5 % -2.6 % 0.1 % WW 421 417 1.0 % -0.2 % 1.2 % 830 839 -1.1 % -1.1 % 0.0 % KNEES US 226 230 -1.9 % -1.9 % - 457 472 -3.1 % -3.1 % - Intl 164 163 0.0 % -2.9 % 2.9 % 322 323 -0.5 % -0.4 % -0.1 % WW 389 394 -1.1 % -2.3 % 1.2 % 778 795 -2.0 % -2.0 % 0.0 % TRAUMA US 501 498 0.7 % 0.7 % - 1,003 1,002 0.1 % 0.1 % - Intl 267 260 2.2 % -1.5 % 3.7 % 537 521 2.9 % 2.8 % 0.1 % WW 768 759 1.2 % -0.1 % 1.3 % 1,540 1,524 1.1 % 1.0 % 0.1 % SPINE, SPORTS & OTHER US 422 430 -1.7 % -1.7 % - 810 862 -6.0 % -6.0 % - Intl 305 314 -2.7 % -6.4 % 3.7 % 588 634 -7.2 % -7.7 % 0.5 % WW 727 743 -2.1 % -3.7 % 1.6 % 1,398 1,495 -6.5 % -6.7 % 0.2 % See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change SURGERY US $ 1,043 995 4.8 % 4.8 % - $ 2,045 1,982 3.2 % 3.2 % - Intl 1,512 1,493 1.3 % -0.2 % 1.5 % 2,906 2,922 -0.5 % 0.3 % -0.8 % WW 2,555 2,488 2.7 % 1.8 % 0.9 % 4,951 4,904 1.0 % 1.5 % -0.5 % ADVANCED US 477 466 2.2 % 2.2 % - 934 912 2.4 % 2.4 % - Intl 687 675 1.9 % 0.2 % 1.7 % 1,303 1,316 -1.0 % -0.4 % -0.6 % WW 1,164 1,141 2.0 % 1.0 % 1.0 % 2,237 2,228 0.4 % 0.8 % -0.4 % GENERAL US 567 528 7.2 % 7.2 % - 1,111 1,070 3.8 % 3.8 % - Intl 825 818 0.9 % -0.6 % 1.5 % 1,603 1,606 -0.1 % 0.8 % -0.9 % WW 1,391 1,346 3.3 % 2.5 % 0.8 % 2,714 2,676 1.4 % 2.0 % -0.6 % VISION US 557 523 6.5 % 6.5 % - 1,123 1,070 4.9 % 4.9 % - Intl 813 763 6.5 % 3.4 % 3.1 % 1,526 1,473 3.6 % 3.7 % -0.1 % WW 1,369 1,285 6.5 % 4.6 % 1.9 % 2,648 2,543 4.1 % 4.2 % -0.1 % CONTACT LENSES / OTHER US 429 409 4.8 % 4.8 % - 881 847 3.9 % 3.9 % - Intl 536 509 5.4 % 1.4 % 4.0 % 1,003 981 2.3 % 1.9 % 0.4 % WW 965 918 5.1 % 2.9 % 2.2 % 1,884 1,828 3.1 % 2.8 % 0.3 % SURGICAL US 128 113 12.6 % 12.6 % - 242 223 8.5 % 8.5 % - Intl 277 254 8.8 % 7.3 % 1.5 % 523 492 6.2 % 7.2 % -1.0 % WW 403 367 9.9 % 8.9 % 1.0 % 764 715 6.9 % 7.6 % -0.7 % TOTAL MEDTECH US 4,383 4,059 8.0 % 8.0 % - 8,596 8,067 6.6 % 6.6 % - Intl 4,158 3,898 6.7 % 4.1 % 2.6 % 7,965 7,711 3.3 % 3.6 % -0.3 % WW $ 8,541 7,957 7.3 % 6.1 % 1.2 % $ 16,561 15,778 5.0 % 5.1 % -0.1 % Expand Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 (6) Acquired on May 31, 2024 Expand
Globe and Mail
09-07-2025
- Business
- Globe and Mail
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
Johnson & Johnson JNJ and Pfizer PFE rank among the world's largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals and medical devices segments. Its pharmaceutical division boasts one of the industry's most varied revenue streams, spanning areas like neuroscience, cardiovascular and metabolic diseases, immunology, oncology, pulmonary hypertension, and infectious diseases. Pfizer, meanwhile, holds a strong leadership position in oncology and also maintains a solid presence in inflammation and immunology, rare diseases and vaccines. Both companies have promising R&D pipelines capable of delivering innovative treatments and supporting future growth. But which stock presents a better investment opportunity right now? Let's dive into their fundamentals, growth outlook and potential challenges to make a well-informed comparison. The Case for J&J J&J's biggest strength is its diversified business model, which helps it to withstand economic cycles more effectively. It operates through more than 275 subsidiaries. J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 4.4% in the first quarter of 2025 on an organic basis despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. In 2025, J&J expects growth in the Innovative Medicine segment in the face of Stelara biosimilar entrants to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J expects its Innovative Medicine business to grow 5-7% from 2025 to 2030. J&J is also making rapid progress with its pipeline and has been on an acquisition spree lately, which has strengthened its pipeline. On the flip side, sales in J&J's MedTech business are facing continued headwinds in the Asia Pacific, specifically in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anti-corruption campaign. J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses. The company lost U.S. patent exclusivity of its blockbuster drug, Stelara, in 2025. The launch of generics is expected to significantly erode the drug's sales, hurting J&J's sales and profits in 2025. J&J faces more than 62,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of its talc-based Johnson's Baby Powder. In April, a bankruptcy court in Texas rejected J&J's proposed bankruptcy plan to settle its talc lawsuits after a two-week trial in Houston. J&J will go back to the traditional tort system to fight the lawsuits individually with its bankruptcy strategy to settle the lawsuits failing for the third time. The Case for PFE Pfizer is one of the largest and most successful drugmakers in oncology. The 2023 acquisition of Seagen strengthened its position in oncology further. After witnessing possibly its worst slowdown in 2023/early 2024, the company seems to be gradually making a comeback and entering a transition phase. With its COVID-related uncertainties diminishing, its revenue volatility is declining. Though COVID revenues are declining, Pfizer's non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Pfizer's significant cost reduction and efforts to improve R&D productivity measures should drive profit growth. However, Pfizer faces its share of challenges, the key being declining sales of its COVID-19 products. Pfizer also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. The Medicare Part D redesign is also expected to hurt sales of Pfizer's higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025. Though Pfizer does not expect strong top-line growth over the next three years due to the LOEs, it expects EPS growth. How Do Estimates Compare for JNJ & PFE? The Zacks Consensus Estimate for J&J's 2025 sales and EPS implies a year-over-year increase of 2.8% and 6.4%, respectively. The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.62 per share for 2025 and from $10.98 per share to $11.00 per share over the past 30 days. JNJ Estimate Movement The Zacks Consensus Estimate for Pfizer's 2025 sales and EPS implies a year-over-year decline of 0.6% and 1.6%, respectively. The Zacks Consensus Estimate for earnings has remained unchanged at $3.06 per share for 2025 and at $3.09 per share for 2026 over the past 30 days. PFE Estimate Movement Price Performance and Valuation of J&J & PFE Year to date, J&J's stock has risen 9.5%, while Pfizer's stock has failed to deliver any returns compared with the industry 's increase of 0.2% Pfizer looks more attractive than J&J from a valuation standpoint. Going by the price/earnings ratio, J&J's shares currently trade at 14.41 forward earnings, slightly lower than 14.93 for the industry. Pfizer's shares currently trade at 8.33 forward earnings, significantly lower than the industry and the stock's 5-year mean of 10.87. Johnson & Johnson's dividend yield is 3.3%, while Pfizer's is 6.7%. Johnson & Johnson's return on equity of 33.5% is higher than Pfizer's 20.3%. PFE or JNJ: Which is a Better Pick? Though Pfizer is on a recovery path, the upcoming patent cliff raises uncertainty. We would like to wait and see how the company navigates through the challenge. Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Meanwhile, J&J, with its Zacks Rank #2 (Buy), improving growth prospects, rising estimates, and recent price appreciation, may prove to be a better pick than Pfizer. J&J has shown steady revenue and EPS growth for years. Though the softness in the MedTech unit and the legal battle surrounding its talc lawsuits are a concern, its Innovative Medicines unit is showing a growing trend. J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps. J&J expects growth to accelerate from 2026 onward. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report
Yahoo
07-07-2025
- Business
- Yahoo
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary arterial hypertension (PAH) and infectious diseases. J&J is scheduled to report second-quarter results on July 16 and investors will be keen to know how the Innovative Medicine segment has performed. Here we discuss some key factors that are likely to have affected the segment's sales in the second quarter. J&J's Innovative Medicine unit is showing a growth trend with sales rising in the segment despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. Higher sales of key products, such as Darzalex, Tremfya and Erleada, due to strong market growth and share gains, are likely to have driven the segment's growth in the second quarter. Sales of some other drugs like Xarelto and Simponi/Simponi Aria are likely to have risen. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant plus Lazcluze and Spravato are also expected to have contributed to growth. However, lower sales of key drugs, Stelara and Imbruvica, and generic/biosimilar competition to drugs like Zytiga and Remicade are likely to have hurt top-line growth. Several biosimilar versions of J&J's multi-billion-dollar immunology drug, Stelara, have been launched in the United States in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. The Stelara LOE hurt revenue growth by 470 basis points in the first quarter of 2025. We expect the negative impact to be steeper in the second quarter. Rising competitive pressure in the United States due to new oral competition is likely to have hurt sales of Imbruvica. Sales of the PAH drug, Uptravi are likely to have been hurt by the impact of Part D redesign, similar to the first quarter, despite market share gains. However, despite Stelara LOE and Medicare Part D headwinds, J&J expects growth in the Innovative Medicine segment in the second quarter and through the rest of the year. Our estimates for the Innovative Medicine unit suggest a CAGR of around 3% over the next three years. Immunology and oncology are J&J's key areas. Other large drugmakers with a strong presence in the oncology market include Novartis, AstraZeneca AZN, AbbVie ABBV, Merck, Bristol-Myers, Roche and Pfizer. In immunology, AbbVie, Amgen, Sanofi, AstraZeneca and Pfizer hold a strong position. J&J's shares have outperformed the industry year to date. The stock has risen 9.6% in the year-to-date period against a 0.6% decline of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.45 forward earnings, lower than 14.86 for the industry. The stock is also trading below its five-year mean of 15.73. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 and 2026 earnings has remained unchanged at $10.60 per share and $10.98 per share, respectively, over the past 60 days. Image Source: Zacks Investment Research J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
02-07-2025
- Business
- Globe and Mail
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary arterial hypertension (PAH) and infectious diseases. J&J is scheduled to report second-quarter results on July 16 and investors will be keen to know how the Innovative Medicine segment has performed. Here we discuss some key factors that are likely to have affected the segment's sales in the second quarter. J&J's Innovative Medicine unit is showing a growth trend with sales rising in the segment despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. Higher sales of key products, such as Darzalex, Tremfya and Erleada, due to strong market growth and share gains, are likely to have driven the segment's growth in the second quarter. Sales of some other drugs like Xarelto and Simponi/Simponi Aria are likely to have risen. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant plus Lazcluze and Spravato are also expected to have contributed to growth. However, lower sales of key drugs, Stelara and Imbruvica, and generic/biosimilar competition to drugs like Zytiga and Remicade are likely to have hurt top-line growth. Several biosimilar versions of J&J's multi-billion-dollar immunology drug, Stelara, have been launched in the United States in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. The Stelara LOE hurt revenue growth by 470 basis points in the first quarter of 2025. We expect the negative impact to be steeper in the second quarter. Rising competitive pressure in the United States due to new oral competition is likely to have hurt sales of Imbruvica. Sales of the PAH drug, Uptravi are likely to have been hurt by the impact of Part D redesign, similar to the first quarter, despite market share gains. However, despite Stelara LOE and Medicare Part D headwinds, J&J expects growth in the Innovative Medicine segment in the second quarter and through the rest of the year. Our estimates for the Innovative Medicine unit suggest a CAGR of around 3% over the next three years. J&J Key Competitors Immunology and oncology are J&J's key areas. Other large drugmakers with a strong presence in the oncology market include Novartis, AstraZeneca AZN, AbbVie ABBV, Merck, Bristol-Myers, Roche and Pfizer. In immunology, AbbVie, Amgen, Sanofi, AstraZeneca and Pfizer hold a strong position. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 9.6% in the year-to-date period against a 0.6% decline of the industry. From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.45 forward earnings, lower than 14.86 for the industry. The stock is also trading below its five-year mean of 15.73. The Zacks Consensus Estimate for 2025 and 2026 earnings has remained unchanged at $10.60 per share and $10.98 per share, respectively, over the past 60 days. J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
